Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen Inc.'s AMGN, -0.11% pipeline of cancer, obesity and cardiovascular drugs is poised to deliver good news for the stock, analysts say, despite the company's recent setback with cancer drug Lumakras.

Amgen's cancer-drug pipeline looks promising despite FDA setback, analysts say

Bank of America

Blackrock Inc

ConocoPhillips

Goldman Sachs

Johnson & Johnson

Coca-Cola

MetLife

Altria

Morgan Stanley

NextEra Energy

Paychex

Pfizer

PNC Financial Services

Phillips 66

Sempra Energy

Texas Instruments

U.S. Bancorp

Vanguard High Dividend Yield ETF

There are 20 stocks on my high yield watchlist for October 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory. An equally weighted portfolio of these stocks underperformed the Vanguard High Yield Dividend ETF by about 0.50% during the month of September.

High Yield Stock Watchlist - October 2023

Airbnb

GlobalFoundries

Global Foundries could benefit from AI-driven demand for chips. Amgen has some weight-loss drugs in the pipeline that could boost the bottom line.

Should You Still Buy the Nasdaq's Best-Performing September Stocks?

AbbVie

With bond yields near historic highs in many instances, stock prices have softened at the onset of Q4. Even so, dividend stocks are still likely to outperform most other asset classes in both the short and long terms.

2 Magnificent Dividend Stocks to Buy Hand Over Fist in October

Horizon Pharma

Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.

Amgen completes $27.8 bln Horizon deal

Amgen Inc. said it would continue to work closely with the Food and Drug Administration to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer, after an advisory panel voted against it at a Thursday meeting.

Amgen to continue to seek full approval of Lumakras cancer drug after FDA panel votes against it

Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial was not reliable enough to support traditional approval of Amgen's Lumakras for patients with a type of advanced lung cancer.

US FDA panel gives thumbs down on approval for Amgen lung cancer drug

REYKJAVIK, Iceland , Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using two platforms of thousands of proteins in samples from large groups from the UK Biobank and Iceland.

Large-scale proteomics in population-based studies from UK and Iceland

Boeing

Salesforce

Chevron

Disney

Dow Inc

Intel

JPMorgan Chase & Co

McDonald's

Microsoft

NIKE

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are October's Dogs of the Dow: JNJ, AMGN, KO, GS, CVX, IBM, DOW, MMM, VZ, and WBA averaged a 4.99% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated October net-gains ranged 17.91%-45.47%, topped by WBA 10/2/23.

October Dogs Of The Dow: 3 Buyable, 7 Watchable

The U.S. Food and Drug Administration's staff reviewers said on Tuesday that Amgen's late-stage study may not provide enough evidence of effectiveness for its lung cancer drug, as the company pursues a traditional approval for the treatment.

FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug

Intuit

Looking at stock returns, INTU has fared better.

Here's Why Intuit Stock Is A Better Pick Over Amgen

Bristol-Myers

Merck

Novartis

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

Drugmakers opt in to Medicare drug price negotiations – here's what happens next

Eli Lilly

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to participate in the talks by the Oct. 1 deadline.

Drugmakers sign on to negotiate Medicare prices under protest

Amgen was the best-performing stock in both the Dow Jones Industrial Average and Nasdaq 100 in the third quarter, while Zions Bancorp, up 32%, was the top stock in the S&P 500.

Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Were Not.

Agilent Technologies

Accenture Plc

AGCO

Applied Materials

Cboe Global Markets

Cencora Inc

Coterra Energy

Microchip Technology

Raymond James

RenaissanceRe Hlds

Steel Dynamics

TFI International

Unum

Visa

Vistra Energy

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable options income strategy. In this monthly series, we present how to go about selecting the right kind of stocks for options income. We present two lists of 10 stocks with multiple scenarios: PUT options, CALL options, and deep-in-the-money CALL options.

Earn Double-Digit Income With Options (October 2023)

Novo Nordisk

The companies that already have obesity drugs can't keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That's because over 42% of the U.S. population was obese as of 2020, while the pervasive publicity around these drugs will make them more popular, and the social and political pressure for insurers to cover the treatments will become more intense.

3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals

Neumora Therapeutics Inc

Neumora Therapeutics stock advanced as much as 16% in Wednesday morning's trade after it was revealed that Amgen Inc (NASDAQ:AMGN) holds a material stake in the company. Amgen was an investor in Neumora's IPO last week, adding to an existing holding, to give it a 23.2% stake in the neuroscience drug discovery company, according to a filing.

Neumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developer

Amgen Inc.'s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.

Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics

BRENTWOOD, Tenn.--(BUSINESS WIRE)---- $AMGN #Cancer--Trilliant Health, the healthcare industry's leading analytics and market research firm, today published its 2023 Trends Shaping the Health Economy Report. The 147-page report is a fact-based national analysis of 10 data-driven trends that will define the landscape, and subsequent challenges, for all players in the health economy. “As a health economist, I study healthcare through the lens of demand, supply and yield,” said Trilliant Health Chief Research Offic.

Trilliant Health's 2023 Trends Shaping the Health Economy Report Offers Data-Driven Insight Into 10 Secular Trends That Will Define the U.S. Healthcare System

Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen.

Amgen Could Get a Piece of the Obesity Market

Arch Resources

Sellers hit the stock market again Tuesday. The Nasdaq composite closed just above 13,000 level, but losers swamped winners on the NYSE.

Stock Market Correction Picks Up Steam; Stocks To Watch Include Amgen, Arch Resources

News for Amgen Stock (AMGN)